<DOC>
	<DOCNO>NCT00277017</DOCNO>
	<brief_summary>The purpose study evaluate therapy combine establish FUNIL regimen Thalidomide . We want see well therapy work , easily do , well body handle treatment . We also wish see addition Thalidomide increase effectiveness already establish treatment regimen .</brief_summary>
	<brief_title>Combination Therapy With 5-Fluorouracil , Interferon-an Interleukin-2 , &amp; Thalidomide Metastatic , Advanced Recurrent Renal Cell Carcinoma</brief_title>
	<detailed_description>Eligible patient agree take part study receive oral dosage Thalidomide 200mg/day start , dosage gradually increase maximum 1200mg/day . This take combination : 5-fluorouracil , give continuous IV infusion 24 hour ( Day 1 ) every week 4 week . Interferon-Î± , give subcutaneously Day 1 , 3 5 every week 4 week . Interleukin-2 , give continuous IV infusion Days 2-5 , every week 4 week . Treatment follow 2 week rest repeat .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>All patient must histologically prove renal cell carcinoma metastatic , nonresectable and/or recurrent . Patients must bidimensionally measurable disease define Section 10.1a document within 28 day prior registration . Xrays , scan , physical exam nonmeasurable disease must complete within 42 day prior registration . Prestudy chest xray must do within 42 day prior registration . Prior treatment drug include protocol permit prior treatment occur 6 month previous patient currently exhibit minor , mixed partial response drug . Prior treatment drug allow long therapy discontinue least one month previously . Prior radiation therapy ( le 25 % bone marrow , see section 19.2 ) , surgery allow . At least 4 week must elapse since completion radiation therapy , must measurable disease outside radiation field . At least 3 week must elapse since completion surgery . Patients must EKG perform within 28 day prior registration . Patients must Southwest Oncology Group performance status 02 define Section 10.4 . Patients must receive plan receive concomitant biologic therapy , radiation therapy , hormonal therapy , chemotherapy protocol ( include G/GMCSF ) . Patients currently untreated brain metastasis brain metastasis current therapy eligible . Patients prior brain metastasis S/P radiation and/or surgery , stable response , confirm MRI , corticosteroid may eligible . Brain MRI within 28 day treatment consultation Study Coordinator require patient . Pregnant nursing woman may participate . Women/men reproductive potential may participate unless agree use effective contraceptive method . Patients serious illness , serious active infection require treatment antibiotic , require ongoing therapy investigational drug receive expect require corticosteroid permit . Patients known AIDS HIV1 associate complex know HIV antibody seropositive eligible . In calculate day test measurement , day test measurement do consider Day 0 . Therefore , test do Monday , Monday four week later would consider Day 28 . This allow efficient patient schedule without exceed guideline . If Day 28 42 fall weekend holiday , limit may extend next working day . Patients must inform investigational nature study give write informed consent accordance institutional federal guideline . Patients must register UNM Cancer Center Protocol Office . All record flow sheet must send office . Active substance abuse lead unexpected dangerous drug interaction toxicity impair compliance ; therefore , condition exclusion registration continuation study . Patients history substance abuse must blood urine test prior registration protocol . Psychosocial screen clinic psychologist social worker also suggest require . Patients find actively engage substance abuse protocol may discontinue protocol treatment direction physician and/or study coordinator .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Combination Therapy</keyword>
	<keyword>5-Fluorouracil</keyword>
	<keyword>Interferon-a Interleukin-2</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>Renal Cell Carcinoma</keyword>
</DOC>